Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons.

Abstract

Eight different human breast carcinoma cell lines, as well as clonally derived cell lines, were used to study the expression of four different monoclonal antibody (MAb)-defined tumor-associated antigens (TAAs) and the ability of recombinant human (rHu)-interferon (IFN)-alpha A and rHu-IFN-gamma to increase tumor-associated and/or normal cell-surface antigen expression. The different breast tumor cell lines expressed a wide range of antigenic phenotypes with respect to four different cell-surface TAAs. The cell lines could be divided into high and low antigen-expressing groups based on their constitutive levels of the four TAAs. In general, those breast tumor cell lines that expressed high levels of carcinoembryonic antigen, the MAb DF-3-defined 290-kD antigen, and the 90-kD antigen reactive with MAb B6.2 were poor candidates for antigen augmentation by rHu-IFN-alpha A or rHu-IFN-gamma. In contrast, breast cell lines that constitutively express low levels of these TAAs were found to be highly responsive to the ability of either of the rHu-IFNs to enhance MAb binding to the cell surface. Treatment with either of the rHu-IFNs increased the level of surface binding of MAbs as much as fourfold. The relative abilities of the IFNs to increase MAb binding to the surface of human breast tumor cells thus appeared to depend on the degree of constitutive surface antigen expression of the breast tumor cells. The high-molecular-weight TAA, TAG-72, is known not to be expressed on most cell lines but is expressed on the majority of human carcinoma biopsies. Most breast tumor cell lines employed in this study did not express the TAG-72 high-molecular-weight TAA. However, rHu-IFN-alpha A did substantially increase the level of expression of TAG-72 on the surface of breast tumor cells that were isolated from a pleural effusion. These studies may thus provide an important insight into the criteria used in the selection of carcinoma patients for IFN-mediated antigen augmentation when employing MAb-guided radioimmunolocalization or MAb-guided therapy.